Table 1.
Main characteristics of all studies included in the meta-analysis
| First author | Year | Patient source | Number of patient | Tumor types | Specimen | Method | PHH3 high expression (%) | Median (range) follow-up (month) | Outcome | M/U | HR (95% CI) | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kim et al15 | 2017 | Korea | 218 | BC | Tissue | IHC | 40.30 | 46 | DFS | U | 8.90 (1.07–74.0) | 9 |
| Chow et al13 | 2017 | People’s Republic of China | 55 | USMT | Tissue | IHC | – | 65.5 | OS | M | 2.71 (1.06–6.94) | 7 |
| Zhu et al8 | 2016 | People’s Republic of China | 61 | Gliomas | Tissue | IHC | 51.67 | 44.3 | OS | M | 1.19 (1.01–1.41) | 8 |
| Winther et al16 | 2016 | Norway | 160 | Meningiomas | Tissue | IHC | – | – | RFS | M | 3.05 (1.46–6.58) | 7 |
| Khan et al19 | 2016 | India | 101 | GC | Tissue | IHC | 58.42 | – | OS DFS |
U U |
2.15 (1.07–4.28) 1.44 (0.61–3.41) |
8 |
| Goltz et al9 | 2015 | Germany | 637 | PC | Tissue | IHC | – | 51 | RFS | U | 1.84 (1.09–3.11) | 8 |
| Iwasaki et al21 | 2015 | UK | 27 | MCC | Tissue | IHC | – | 42 | OS | M | 7.47 (1.41–39.61) | 6 |
| Ramani et al22 | 2015 | UK | 80 | Neuroblastomas | Tissue | IHC | 30.00 | 121.3 | OS | M | 2.60 (1.10–5.80) | 8 |
| Alkhasawneh et al11 | 2015 | USA | 50 | GSTS | Tissue | IHC | 34.00 | 56.4 | OS | U | 0.97 (0.36–2.62) | 7 |
| Gerring et al24 | 2015 | New Zealand | 108 | BC | Tissue | IHC | – | 85 | OS | M | 4.35 (2.17–8.71) | 7 |
| Olar et al23 | 2015 | USA | 363 | Meningiomas | Tissue | IHC | 15.42 | – | RFS | U | 1.03 (1.02–1.05) | 8 |
| Duregon et al27 | 2014 | Italy | 48 | AC | Tissue | IHC | – | 40 | OS | U | 2.22(1.0–5.0) | 6 |
| Xu14 | 2014 | China | 52 | PC | Tissue | IHC | 94.23 | – | OS | M | 5.43 (1.24–23.80) | 6 |
| Klintman et al25 | 2013 | Sweden | 221 | BC | Tissue | IHC | 30.77 | – | DFS | U | 2.40 (1.40–4.30) | 8 |
| Gudlaugsson et al17 | 2013 | Norway | 237 | BC | Tissue | IHC | 35.44 | – | RFS DFS |
M M |
10.6 (4.4–25.6) 8.9 (3.4–23.5) |
8 |
| Ladstein et al18 | 2012 | Norway | 338 | CNM | Tissue | IHC | 74.85 | 61.5 | OS | M | 1.90 (1.04–3.36) | 9 |
| Brunner et al26 | 2012 | Australia | 99 | EC | Tissue | IHC | 48.48 | 72 | OS | M | 5.9 (1.7–31.4) | 8 |
| Gudlaugsson et al10 | 2011 | Norway | 240 | BC | Tissue | IHC | 35.00 | 117 | OS | M | 9.6 (3.1–29.9) | 9 |
| Kim et al20 | 2007 | Germany | 99 | Meningiomas | Tissue | IHC | – | 42 | RFS | M | 1.07 (1.06–1.10) | 8 |
Note:
‘–’ unobtainable data.
Abbreviations: AC, adrenocortical carcinoma; BC, breast cancer; CNM, cutaneous nodular melanoma; DFS, disease-free survival; EC, endometrial carcinoma; GC, gastric cancer; GSTS, gastrointestinal stromal tumors; IHC, immunohistochemistry; M, multivariate; MCC, Merkel cell carcinoma; NOS, Newcastle–Ottawa scale; OS, overall survival; PC, prostate carcinoma; PHH3, phospho-histone-H3; RFS, recurrence-free survival; U, univariate; USMT, uterine smooth muscle tumor.